Amarin Corporation PLC
amarincorp.comWhat Do They Do?
Sells VASCEPA and VAZKEPA, prescription medicines for reducing cardiovascular risk, through wholesalers, pharmacies and commercial partners.
10-K for FY2025, filed Mar 2, 2026Our commercialized product, VASCEPA® (icosapent ethyl) was first approved by the United States, or U.S., Food and Drug Administration, or…View ↗
On March 26, 2021, the European Commission, or EC, approved the marketing authorization application for VASCEPA, under the brand name…View ↗
VASCEPA is sold principally to a limited number of major wholesalers, as well as selected regional wholesalers and retail and mail order…View ↗
How Do They Make Money?
U.S. distributors buy VASCEPA and generally pay 45 days after sale; international partners buy product at contract net prices. Amarin also earns licensing and royalty revenue, including through Recordati’s long-term license to commercialize VAZKEPA.
10-K for FY2025, filed Mar 2, 2026The Company sells VASCEPA principally to a limited number of major wholesalers, as well as selected regional wholesalers and specialty…View ↗
Within the U.S., revenues from product sales are recognized when the distributor obtains control of the Company’s product, which occurs at…View ↗
Outside of the U.S., our product revenue is derived from the sales of VASCEPA to our commercial partners based on the net price for VASCEPA…View ↗
In June 2025, we entered into an exclusive long-term license and supply agreement with Recordati, or the Recordati Licensing Agreement…View ↗
-
10-K for FY2025, filed Mar 2, 2026
FY2025 revenue by product or service ↗
$213.6M
-
10-K for FY2025, filed Mar 2, 2026
$213.6M ↗
| Segment | Share | Revenue | How money arrives |
|---|---|---|---|
|
Product Revenue, Net
Sold outright
10-K for FY2025, filed Mar 2, 2026 |
86%
FY2022: 99%
|
Product Revenue, Net, FY2025
$182.8M Sources
|
Sold outright |
|
Licensing and Royalty Revenue
Licensed
10-K for FY2025, filed Mar 2, 2026 |
14%
FY2022: 0.7%
|
Licensing and Royalty Revenue, FY2025
$30.9M Sources
|
Licensed |
Who Are Their Customers?
Amarin sells chiefly to major and regional wholesalers and pharmacy providers in the U.S., and to established commercial partners globally. Most distributors resell VASCEPA to retail pharmacies, which then sell it by prescription to patients.
10-K for FY2025, filed Mar 2, 2026The Company sells VASCEPA principally to a limited number of major wholesalers, as well as selected regional wholesalers and specialty…View ↗
Do Revenues Turn Into Profits?
No. It lost $38.8M in FY2025.
10-K for FY2025, filed Mar 2, 2026
How Are They Changing?
- Net income
-
Sources
10-Q for Q2 FY2026, filed Jul 29, 2026
−$7.7MView ↗
- ▼ −46% (Loss)
- vs −$14.1M in Q2 FY2025
10-Q for Q2 FY2026, filed Jul 29, 2026
Open tableView ↗
Shrinking. Revenue fell 63% in 4 years, from $583.2M in FY2021 to $213.6M in FY2025, about 22% a year.
European commercialization moves to a partner
The older report described building European commercial teams and using outside support; the latest report gives Recordati sole responsibility for commercializing VAZKEPA in its territory under a license and supply agreement.
10-K for FY2022, filed Mar 1, 2023 10-K for FY2025, filed Mar 2, 2026In order to launch impactfully throughout Europe, we are building a core team of experienced professionals and highly capable local…View ↗
In June 2025, we entered into an exclusive long-term license and supply agreement with Recordati, or the Recordati Licensing Agreement…View ↗
Who Do They Compete With?
Competes with Hikma Pharmaceuticals USA, Dr. Reddy’s Laboratories, Teva Pharmaceuticals USA, Apotex, Zydus Lifesciences, Amneal Pharmaceuticals, Epic Pharma, Ascent Pharmaceuticals, Qilu Pharmaceutical, PharmaObedient, Xiamen LP Pharma, Woodward Pharma Services, AbbVie, AstraZeneca, and Kowa
10-K for FY2025, filed Mar 2, 2026Company (ANDA Holder) Distributed / Licensee FDA MARINE Indication Approval 1-gram Launch Date 0.5-gram Launch Date Active Hikma…View ↗
Loading...
